title: Prevalence of plasmid-mediated AmpC β-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum β-lactamase-producing E. coli in Japan.
abstract: In 2010, a total of 1327 clinical Escherichia coli isolates from five hospitals in the Kyoto and Shiga regions of Japan were analysed by PCR. The prevalences of plasmid-mediated AmpC β-lactamase (pAmpC)-producers, extended-spectrum β-lactamase (ESBL)-producers and co-producers of pAmpC and ESBL were 1.7%, 9.7% and 0.3%, respectively. Less than one-half of the pAmpC-producers were reported to be resistant to third-generation cephalosporins, cephamycins and β-lactam/β-lactam inhibitors using the old 2009 Clinical and Laboratory Standards Institute (CLSI) breakpoints. CMY-2 was the most prevalent pAmpC type (95%), and CTX-M-14 (38%), CTX-M-15 (26%) and CTX-M-27 (19%) were the most prevalent ESBL types. The worldwide O25b-ST131-B2 clone accounted for 11% of pAmpC-producers and 41% of ESBL-producers. The O25b-ST131-B2 clone was characterised by a CTX-M-27- or CTX-M-15-type ESBL and ciprofloxacin-non-susceptibility with quadruple mutations in the quinolone resistance-determining regions (S83L and D87N in GyrA and S80I and E84V in ParC). A significant proportion of pAmpC-producers and the O25b-ST131-B2 clone were found in Japan by a recent regional surveillance programme.
authors: Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. yazblood@kuhp.kyoto-u.ac.jp
authors: Yasufumi
authors: Y
authors: Matsumura
authors: Masaki
authors: M
authors: Yamamoto
authors: Takeshi
authors: T
authors: Higuchi
authors: Toshiaki
authors: T
authors: Komori
authors: Fusayuki
authors: F
authors: Tsuboi
authors: Akihiko
authors: A
authors: Hayashi
authors: Yoshihisa
authors: Y
authors: Sugimoto
authors: Gou
authors: G
authors: Hotta
authors: Aki
authors: A
authors: Matsushima
authors: Miki
authors: M
authors: Nagao
authors: Shunji
authors: S
authors: Takakura
authors: Satoshi
authors: S
authors: Ichiyama
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000096:biosynthesis* / Q000235:genetics; D002442:Ceftazidime / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D027081:DNA Gyrase / Q000096:biosynthesis / Q000235:genetics; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000145:classification / Q000187:drug effects / Q000201:enzymology* / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000453:epidemiology / Q000382:microbiology; D029968:Escherichia coli Proteins / Q000096:biosynthesis / Q000235:genetics; D005798:Genes, Bacterial; D006761:Hospitals; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008826:Microbial Sensitivity Tests; D010802:Phylogeny; D010957:Plasmids / Q000235:genetics / Q000378:metabolism*; D015995:Prevalence; D001618:beta-Lactamases / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D029968:Escherichia coli Proteins; D002939:Ciprofloxacin; D002442:Ceftazidime; C477098:CTX-M-27, E coli; C456080:beta-lactamase CTX-M-14; C473109:beta-lactamase CTX-M-15; C048795:AmpC beta-lactamases; D001618:beta-Lactamases; D027081:DNA Gyrase